
Join SOPHiA GENETICS at the European Human Genetics Conference (ESHG) 2026 in Gothenburg, Sweden! Find us at Booth #214, where our experts will be ready to discuss the latest in genomic testing for rare and inherited disease research.
Explore our newest applications, including enhanced clinical and whole exomes (WES), whole genome sequencing (WGS), and our extended pharmacogenomics solution, all connected through a single sample-to-report workflow with seamless EHR and LIMS integration of the SOPHiA DDM™ Platform linked with Alamut™ Visual Plus.
Come discover how SOPHiA DDM™ and Alamut™ Visual Plus can support your lab from sample to clinical insight.
Corporate Session
Join our Corporate Session as leading European laboratories share practical approaches to scaling genomic workflows across transcriptomics, WES, and WGS, all powered with our SOPHiA DDM™ Platform and Alamut™ Visual Plus.
Saturday, 13 June | 12:15pm – 1:30pm | Room A6
New approaches to molecular interpretation in clinical genomics: From transcriptomics to exome and genome sequencing
Minna Paavola, Clinical Laboratory Geneticist, Turku University Hospital, Finland
Tobias Bethge, PhD, Molecular Geneticist, Genetica AG, Switzerland
Gorka Alkorta-Aranburu, PhD, Laboratory Director, Clínica Universidad de Navarra, Spain
Sevana Yaghoubian, MSc, Senior Director of Product Management, SOPHiA GENETICS
Poster Presentations
Comprehensive genome analysis with SOPHiA DDM™ for low-pass and 30x WGS
- presented by Izabela Matyszczak, PhD, Technical Product Management Expert - Genomic Research at SOPHiA GENETICS
Sunday, 14 June | 12:45pm to 1:45pm | P20.159.C
Excelsa: A variant prioritization algorithm integrating variant- and phenotype-level evidence
- presented by Giulia Muzio, PhD, Bioinformatician - Tertiary Analysis at SOPHiA GENETICS
Sunday, 14 June | 3:45pm to 4:45pm | P15.094.D
Meet the Experts Networking Session
Join us at our booth to connect with our genomics experts and take part in engaging conversations with peers and industry professionals.
Saturday, 13 June | 3:45pm to 4:45pm | Booth #214
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.